Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatrics.

This exposure-response analysis suggests that DTG exposures in children are all above the plateau of the exposure-response relationship. These results suggest that matching pediatric pharmacokinetic exposure parameters to those in adults is a reasonable approach for dose determination of DTG-containing formulations in pediatrics.